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Summary Clinical data from 369 patients with clinical stage cutaneous malignant melanoma treated in Kuopio University Hospital district
between 1974 and 1989 with a mean follow-up of 6.4 years were analysed. Clinical parameters, histology, DNA index, S-phase fraction (SPF)
and mitotic indices [mitotic activity index (MAI) and volume-corrected mitotic index (MN index)] were correlated with the outcome of the
disease to establish their value as predictors of stage cutaneous malignant melanoma. In univariate survival analyses, bleeding, gender,
tumour thickness, level of invasion according to Clark, TNM category, MAI, MN index and SPF were the most significant predictors of
recurrence-free (RFS) and overall survival. In Cox's multivariate analysis, tumour thickness (P = 0.0021), bleeding (P = 0.0106) and MN
index (P = 0.0058) predicted poor RFS in the 259 patients available for the analysis. Poor overall survival was predicted by MAI (P= 0.0002),
bleeding (P = 0.004), SPF (P = 0.009) and male gender (P = 0.034). The present results indicate that mitotic activity index (MAI), volume-
corrected mitotic index (MN index) and S-phase fraction (SPF) are important prognostic factors in addition to the well-established Breslow
thickness in stage cutaneous malignant melanoma.
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Previous studies have shown that tumour thickness according to
Breslow is the most important predictor of disease outcome in
local cutaneous malignant melanoma (Breslow, 1970; Eastwood
and Baker, 1984; Gattuso et al, 1990; Garbe et al, 1995; Barnhill
et al, 1996; Straume and Akslen, 1996). Location of the tumour
(Salman and Rogers, 1990), sex of the patient (Salman and
Rogers, 1990), level of tumour invasion by Clark (Straume and
Akslen, 1996), prognostic index (Schmoeckel and Braun-Falco,
1978), histological type (Garbe et al, 1995; Barnhill et al, 1996),
age at diagnosis (Garbe et al, 1995) and histological ulceration
(Straume and Akslen, 1996) are also important prognostic factors
in localized cutaneous melanoma.
One method of assessing cell proliferation in routinely fixed
histological sections is mitotic counting, which has been related to
patient survival in several human malignancies (Eskelinen et al,
1992; Cross and Start, 1996). Univariate (Ramsay et al, 1995;
Clemente et al, 1996) and multivariate (Barnhill et al, 1996;
Straume and Akslen, 1996) survival analyses have also revealed
the value of mitotic rate as a prognosticator in stage I cutaneous
melanoma, whereas contradictory results have been reported
(Talve et al, 1996). DNA index (DI) has been related to the bio-
logical behaviour of human solid malignancies (Friedlander et al,
1984), including stage I cutaneous malignant melanoma (von
Roenn et al, 1986; Kheir et al, 1988; Gattuso et al, 1990;
Bartkowiak et al, 1991). There are no previous studies on mitotic
indices, S-phase fraction and DNA index in stage I cutaneous
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malignant melanoma using multivariate survival analysis. The
present study was conducted to assess the applicability of mitotic
rate, SPF and DI in stage I cutaneous malignant melanoma and
to analyse their inter-relationship and relation to traditional
prognostic factors of cutaneous melanoma as well as to patient
survival.
PATIENTS AND METHODS
Patients
This retrospective study consisted of 369 patients diagnosed and
treated for clinical stage I cutaneous malignant melanoma in the
district of Kuopio University Hospital between 1974 and 1989.
The patients were selected from 473 consecutive stage I melanoma
patients, based on the availability of sufficient material from the
primary tumour. The clinical staging of all tumours was done
according to UICC (UICC, 1987). Patient records were reviewed
and the pertinent clinical data are shown in Table 1. The mean
follow-up time of the patients was 6.4 years (range 0.2-18 years).
The cause ofdeath was obtained from the patient records and from
the files of the Finnish Cancer Registry and General Statistical
Office in Finland.
Histological methods
The tumour samples were fixed in buffered formalin (pH 7.0),
embedded in paraffin, sectioned at 5 gm and stained with haema-
toxylin and eosin (HE). The histological diagnosis was confirmed
by reviewing one to four original sections of the primary tumour.
Tumour thickness according to Breslow (1970) and level of inva-
sion according to Clark et al (1969) were re-examined by the same
pathologist (VMK), unaware of the clinical data.
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Table 1 Clinical and histopathological data of 369 patients DNA flow cytometry
Gender
Female
Male
Age (years)
Mean (s.d.)
Range
Anatomic site
Head and neck
Trunk and perineum
Upper limbs
Lower limbs
Bleeding of the primary tumour
Yes
No
Data not available
Growth of the primary tumour
Yes
No
Data not available
Cause of death
Malignant melanoma
Other
Alive
Recurrent disease
Yes
No
Clark level
11
III
IV
V
Tumour thickness (mm)
<0.75
0.76-1.50
1.51-4.0
>4.0
Not possible to analyse
TNM category
pTl-T2,NO,MO
pT3,NO,MO
pT4,NO,MO
Adjacent to HE sections analysed for their tumour content, two 50-
191 gm-thick sections were cut for DNA flow cytometry. For flow
178 cytometry, a slightly modified version of the method of Hedley et
al (1983) was applied. The sections were treated with 10 mg ml
55.5 (15.2) proteinase K (Sigma, St Louis, MO, USA) for 30 min at room
temperature and filtered through a 50-gm nylon mesh. The nuclei
were treated with 10 mg ml RNAase and stained with 25 ,ug ml
173 ethidium bromide (Sigma) for at least 1 h. The DNA was
58 determined by flow cytometry (FACScan; Becton-Dickinson,
74 Mountain View, CA, USA) using 15 mW excitation at 488 nm.
The total emission above 560 nm was recorded, and at least 10 000
98 nuclei from each specimen were analysed. No internal standard
152 was added, as the staining intensity varied from sample to sample.
119 The lowest peak was assigned a DNA index (DI of 1.00), and the
DI values of other peaks were calculated using this as a reference.
200 Therefore, possible hypodiploid peaks were identified as diploid
38 and the normal diploid peak as hyperdiploid. Tumours with one 131
peak were considered to be diploid, and those with more than one
66 peak aneuploid. The histograms were interpreted by one of us
46 (SN), unaware of the clinical outcome.
257 A full peak (GO/G1) coefficient of variation (CV) was calcu-
lated, and only samples with a CV of less than 10% were accepted
106 for furtheranalysis. This was done because, in samples with a high
263 CV, a near-diploid peak (DI < 1.1) could remain undetected.
The S-phase fraction was calculated either using the Cellfit
21 program of the FACScan flow cytometer or manually by a modi-
68 fied rectilinear method (Baisch et al, 1975; Camplejohn et al,
106 1989). The SPF of the stem line with the highest DI was calcu-
29 lated. In cases with different SPF values obtainedby the automatic
and manual methods, the lower value was chosen. Usually the
82 manual method gave a lower result, because it was applied only in
88 tumours in which the automatic method seemed to give too high
120 values. In these cases, there was usually a skewness to the right of
2° the G1 peak or a noticeable G2 peak of the diploid population
29 within the S-phase ofthe aneuploid population.
174
139
56
Mitotic indices
The mitotic figures were ranked in ten consecutive high-power
fields (HPF) where mitotic activity was highest. The mitotic
activity index (MAI) is the number of sharply defined mitoses per
ten HPF without consideration of the percentage representing
tumour tissue. The volume-corrected mitotic index (MIV index)
was determined by the method and formula originally introduced
by Haapasalo et al (1989a). The MN index expresses the number
of mitotic figures mm-2 of neoplastic tissue in the microscope
image. Both measurements were done by one investigator (JK)
and, thus, interobserver variation was avoided. All mitotic figures
were counted using an objective magnification of 40 x (field
diameter 490 ,um) with an Olympus Vanox T microscope. In 37
specimens, there was not enough tumour material to measure ten
consecutive high-power fields; these were therefore excluded.
Thus, mitotic indices from 332 patients were analysed.
Statistical analyses
The SPSS-Win program package was used in a PC computer for
basic statistical calculations. The statistical tests used are indicated
in the results when appropriate. Correlations of categorical vari-
ables were examined by contingency tables, which were further
analysed by chi-square tests (Pearson correlation coefficient).
Univariate survival analyses were based on the Kaplan-Meier
method (log rank analysis; Kaplan and Meier, 1958). Multivariate
survival analysis was done with the SPSS-Cox (Cox, 1972)
programme package using a forward stepwise procedure and the L
ratio significance test. Overall survival analysis included as an
event only the deaths resulting from malignant melanoma. Deaths
attributable to post-operative complications within 30 days were
excluded. Recurrence-free survival (RFS) was defined as the time
elapsed between the primary treatment and the recurrent tumour.
For all statistical tests, a critical significance level of 5% was
chosen. In Cox's multivariate analysis, a removal limit ofP < 0. 0
was used as an additional inclusion criteria.
RESULTS
There were 191 women (52%) and 178 men (48%) in the
cohort. The mean age was 55.5 years (s.d. 15.2) with a range of
British Journal of Cancer (1998) 77(11), 1917-1925 0 Cancer Research Campaign 1998Prognosis in cutaneous malignant melanoma 1919
Table 2 Association of cell proliferative activity (MAI, MN index) with clinicopathological parameters.
Clinicopathological variable No. of patients MAI MN index
<1 (%) >1 (%) P 7 > 7(%) P
Bleeding 332 <0.000005a 0.00002a
Yes 94 32 68 28 72
No 132 65 35 58 42
NAb 106 57 43 52 48
Gender 332 0.13 0.80
Male 162 49 51 47 53
Female 170 57 43 48 52
Anatomic site 332 0.01 0.01
Head and neck 54 35 65 28 72
Trunk and perineum 161 60 40 53 47
Upper limbs 51 47 53 53 47
Lower limbs 66 55 45 46 54
Age at diagnosis 332 0.03 0.02
s55 years 153 60 40 54 46
>55 years 179 48 52 42 58
Co-existing naevus 332 0.65a 0.34a
Yes 153 52 48 45 55
No 60 50 50 43 57
NAb 119 56 44 53 47
Clark level 332 <0.000005 <0.000005
8 88 12 50 50
11 60 88 12 72 28
III 96 67 33 59 41
IV 140 34 66 34 66
V 28 18 82 25 75
Tumour thickness (mm) 316 <0.000005 <0.000005
< 0.75 71 90 10 73 27
0.76-1.50 80 69 31 63 37
1.51-4.0 115 31 69 32 68
> 4.0 50 16 84 22 78
Numbers in cells indicate percentage of the patients in each category of clinicopathological variables. MAI, mitotic activity index (mitoses/HPF; objective
magnification x 40; field diameter, 490 um). MV index, volume-corrected mitotic index (mitoses mm-2 of neoplastic tissue in a section). aNA category used as an
intermediate category in the analysis; bNA, data not available.
19.0-90.0 years. The most common location was the trunk and
perineum (47%); 20% were in the lower limbs, 16% in the upper
limbs and 17% in the head and neck area.
In the statistical analyses for mitotic rates and SPF, we used the
median as the cut-offvalue (1 for MAI, 7 for MN index and 4% for
SPF respectively). The associations between tumour proliferative
activity indicators (MAI, MN index and SPF) and conventional
clinicopathological parameters are shown in Tables 2 and 3. There
was a significant association between high (>4%) SPF and high
mitotic frequency measured by MAI (P = 0.002) and MN index
(P = 0.001). The association ofMAI with SPF is shown in Table 4.
During the follow-up, 106 patients (29%) had a recurrence, 66
patients (18%) died of melanoma and 46 patients (13%) died of
other causes. The crude 5-year survival rate ofthe patients was 78%.
The overall 5-year survival rate of the patients was 85%, and the
5-year RFS rate was 76%.
Clinical, histological and quantitative features predicting RFS
and overall survival are shown in Table 5. The most important
clinical predictors of RFS in univariate analysis were bleeding and
gender. From the histological variables studied, TNM, tumour
thickness (Figure 1) and the Clark level ofinvasion were all highly
significant predictors. MAI, MN index and SPF were the most
important quantitative variables predicting RFS. Significant
factors predicting overall survival in univariate analysis were
gender (Figure 2), bleeding (Figure 3), tumour thickness, Clark
level of invasion, TNM category, MAI (Figure 4), MN index and
SPF (Figure 5).
A multivariate Cox analysis was performed on 259 patients with
a complete set ofdata available. It included only the variables that
were significant in univariate analysis (gender, bleeding, tumour
thickness, Clark level ofinvasion, MAI, M/V index and SPF). The
pT category (consisting of Clark level of invasion and tumour
thickness) was excluded from the final model. Tumour thickness
(P = 0.0021), bleeding (P = 0.0106) and high MN index
(P = 0.0058) predicted poor recurrence-free survival. High MAI
(P = 0.0002), bleeding (P = 0.004), high SPF (over 4%; P = 0.009)
and male gender (P = 0.034) were statistically significant predic-
tors ofpoor overall survival (Table 6).
In order to address whether mitotic rates or SPF add significant
information to normally available clinical prognosticators, we
combined the proliferation markers (MAI, M/V index and SPF)
with conventional variables (tumour thickness, bleeding and
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Table 3 Association of SPF with clinicopathological parameters
Clinicopathological No. SPF
variable of patients
<4% (%) >4% (%) P
Bleeding 290 0.05a
Yes 77 44 56
No 119 61 39
NAb 94 51 49
Gender 290 0.47
Male 144 56 44
Female 146 52 48
Anatomic site 290 0.01
Head and neck 50 38 62
Trunk and perineum 143 59 41
Upper limbs 42 64 36
Lower limbs 55 44 56
Age at diagnosis 290 0.19
< 55 years 130 58 42
> 55 years 160 50 50
Co-existing naevus 290 0.78a
Yes 135 53 47
No 50 58 42
NAb 105 52 48
Clark level 290 0.0007
13 77 23
11 56 71 29
III 78 56 44
IV 119 45 55
V 24 29 71
Tumour thickness (mm) 270 0.0001
< 0.75 64 67 33
0.76-1.50 67 64 36
1.51-4.0 99 45 55
>4.0 40 27 73
Numbers in cells indicate percentage of the patients in each category of
clinicopathological variables. SPF, S-phase fraction. aNA category used as an
intermediate category in the analysis; bNA, data not available.
gender) respectively. We also combined MAI and SPF in the
same manner. Each of these combinant variables (MAIl
Breslow, MAI/bleeding, MAI/gender, MAIISPF, SPF/Breslow,
SPF/bleeding and SPF/gender for overall and MN index/Breslow
and M/V index/bleeding forrecurrence-free survival) were used in
turn with the other remaining independent variables in a Cox
forward stepwise manner.
In overall survival, MAI/bleeding (P = 0.0035) and MAI/SPF
(P = 0.0001) were those variables that clearly added prognostic
power to the model. In patients with bleeding tumours, the relative
risk of melanoma death was 9.05 (CI 2.1-39.7) in the high MAI
(> 1) subgroup compared with the risk of patients with non-
bleeding tumours in the low MAI (< 1) subgroup. The relative risk
of melanoma death for the patients with high MAI (> 1) and high
SPF (> 4%) categories was 10.6 (CI 3.2-35.6) compared with the
risk ofpatients with low MAI (< 1) and low SPF (< 4%) categories
(other data not shown). In the recurrence-free survival analysis,
the MN index/Breslow variable was a better prognosticator
(overall P = 0.0002) than either MN index or Breslow thickness.
The risk of melanoma recurrence between the patients with
Table 4 Association of mitotic activity index (MAI) and S-phase fraction
(SPF)
SPF MAI
< 1 (number of patients = 142) > 1 (number of patients = 131)
< 4% 62% 44%
> 4% 38% 56%
Total 100% 100%
Numbers in cells express percentage of the patients in each MAI category.
%2 = 9.32; P = 0.002. SPF, S-phase fraction; MAI, mitotic activity index
(mitoses/HPF, objective magnification x 40, field diameter, 490 gm).
tumour thickness > 4.0 mm and MN index > 7 was 38.3
(CI 5-293) compared with the risk of patients with tumour thick-
ness < 0.75 mm and MN index < 7 (other data not shown).
DISCUSSION
The proliferative activity of cancer cells has a significant prog-
nostic value in several human malignancies (Quinn and Wright,
1990). Mitotic counting is the most commonly used method of
assessing proliferative activity in human tumours. The mitotic
activity has an independent prognostic value in many human
epithelial tumours (Cross and Start, 1996). In malignant
melanoma, mitotic counts have been shown to be of prognostic
significance in several studies (Schmoeckel and Braun-Falco,
1978; Salman and Rogers, 1990; Evans et al, 1992; Ramsay et al,
1995; Clemente et al, 1996).
The potential value ofthe mitotic index as a prognostic parameter
has been questioned because different authors have obtained
varying results (Quinn and Wright, 1990). The variability in fixa-
tion, intratumoral heterogeneity, variations in cell size and the
criteria forrecognition ofmitotic figures may all cause interobserver
variations (Weidner et al, 1994; Collan et al, 1996; Cross and Start,
1996; Jannink et al, 1996). The reproducibility ofthe MNV index and
MAI have been documented in human tumours (Donhuijsen, 1986;
Montironi et al, 1988; Haapasalo et al, 1989b; Lipponen et al, 1990).
Jannink et al (1996) found a high degree of intratumour hetero-
geneity of mitotic activity (MAI and MNV index) in breast cancer.
They conclude that multiple blocks should be taken, and the areas
with highest proliferation should be selected. According to their
results, a correction for the volume percentage ofepithelium did not
result in remarkable heterogeneity in results between MAI and MN
index. As long as the criteria to assess the mitotic activity are strict,
the mitotic index will be reproducible and prognostically relevant.
Flow cytometric analysis of nuclear DNA content and SPF is
a feasible method for estimating the malignant potential and
growth characteristics of malignant tumours (Seckinger et al,
1989; Keshgegian and Cnaan, 1995). DNA aneuploid primary
melanomas recur earlier and more frequently than do DNA diploid
ones (von Roenn et al, 1986; Kheir et al, 1988). DNA aneuploidy
has also been associated with a shorter survival in primary
melanoma (Kheir et al, 1988; Lindholm et al, 1989; Gattuso et al,
1990; Bartkowiak et al, 1991). In our study, DNA ploidy had no
impact on survival. Differences in tissue processing, the nuclei
measured, DNA histogram/cell cycle analysis and intratumoral
heterogeneity may explain the above-mentioned divergent results
(Kallioniemi, 1988; Bergers et al, 1996).
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Table 5 Clinical, histological and quantitative factors related to survival in cutaneous malignant melanoma
Category (variable) No. of Recurrence-free 5 pa Surviving at 5 pa
patients years (RFS) (%) years (%)
Gender
Male 178 75 0.0113 79 0.0056
Female 191 89 89
Bleeding
Yes 98 74 <0.00005b 77 0.0002b
No 152 90 92
NAc 119 79 83
Clark level
21 94 <0.00005 94 <0.00005
11 68 98 98
III 106 90 92
IV 145 71 76
V 29 65 65
Tumour thickness (mm)
< 0.75 82 97 <0.00005 97 <0.00005
0.76-1.50 88 90 93
1.51-4.0 120 74 78
> 4.0 50 57 63
TNM category
pTl-T2,NO,MO 174 95 <0.00005 96 <0.00005
pT3,NO.MO 139 74 78
pT4,NO,MO 56 60 65
MAI
< 1 176 92 <0.00005 93 <0.00005
> 1 156 69 74
MN index
<7 158 91 <0.00005 93 <0.00005
> 7 174 72 77
SPF
<4% 155 91 0.0001 92 0.0007
> 4% 135 72 76
DNA ploidy
Diploid 237 83 0.15 85 0.25
Aneuploid 57 74 80
aLog rank analysis. bNA category used as an intermediate category in the analysis. CNA, data not available. MAI, mitotic activity index; MN index, volume-
corrected mitotic index; SPF, S-phase fraction.
Like DNA ploidy, SPF has aprognostic value in cutaneous stage
I (Bartkowiak et al, 1991) and metastatic (Muhonen et al, 1992)
melanoma. Our study supports the important prognostic role of
SPF in malignant melanoma. High SPF (over 4%) predicted poor
recurrence-free and overall survival in univariate analysis and poor
overall survival in multivariate analysis. However, in order to use
SPF as a marker of cell proliferative activity, we have to consider
that SPF varies considerably in different samples from the same
tumour (Kallioniemi, 1988). SPF does not indicate the growth rate
of the tumour directly, but merely indicates the proportion of cells
synthesizing DNA.
Other cell proliferation markers that can be used on routine
tissue sections are Ki-67 antigen, proliferative cell nuclear antigen
(PCNA) and silver-binding nucleolar organizer region (AgNOR)
staining (Cross and Start, 1996). Ki-67 antigen can be detected
with either a polyclonal Ki-67 antibody or a specific monoclonal
antibody for Ki-67 epitope (MIB-1; Gerdes et al, 1991). MIB-1
expression correlates with mitotic counts in breast and renal cell
carcinoma (Weidner et al, 1994; Cross and Start, 1996; Jochum et
al, 1996), but it is liable to the same reproducibility problems as
mitotic counts. MIB-1 staining had a prognostic independent value
even superior to tumour thickness and mitotic index in primary
thick cutaneous melanomas (Ramsay et al, 1995). In addition,
immunostaining for Ki-67 antigen is helpful in identifying individ-
uals with thick nodular melanomas who are at risk of metastatic
disease (Vogt et al, 1997). PCNA expression in cutaneous
melanomas seems to be a marker of tumour progression
(Takahashi et al, 1991; Evans et al, 1992), but it may not help in
predicting prognosis in these tumours (Reddy et al, 1995). AgNOR
counts often correlate with other markers of cell proliferation, but
the staining techniques and the counting methods suffer standard-
ization problems (Cross and Start, 1996). So far, AgNOR counting
has failed in predicting the prognosis of cutaneous malignant
melanoma, and its correlation with other cell proliferation markers
in cutaneous melanomas is also controversial (Evans et al, 1992).
In our study, the most important prognostic factors observed in
univariate analyses (Table 5) were bleeding of the tumour, gender
of the patient, tumour thickness according to Breslow, level of
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Figure 1 Recurrence-free survival according to Breslow thickness in stage
cutaneous malignant melanoma (tumour thickness < 0.75 mm, n = 82;
tumour thickness 0.76-1.50 mm, n = 88; tumour thickness 1.51-4.0 mm,
n = 120; tumour thickness > 4.0 mm, n = 50; P < 0.00005; x2 = 52.67)
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Figure 2 Overall survival of women (n = 191) and men (n = 178) in stage
cutaneous malignant melanoma (P = 0.0056; x2 = 7.66)
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Figure 3 Overall survival according to bleeding in stage cutaneous
malignant melanoma (no bleeding, n = 152; bleeding, n = 98; bleeding
unknown, n = 119; P= 0.0002; x2 = 17.36)
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Figure 4 Overall survival according to MAI in stage cutaneous malignant
melanoma (MAI < 1, n = 176 and MAI > 1, n = 156; P < 0.00005; x2 = 31.51)
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Figure 5 Overall survival according to SPF in stage cutaneous
malignant melanoma (SPF < 4%, n = 155 and SPF > 4%, n = 135;
P= 0.0007; X2 = 11.43)
invasion according to Clark, TNM category and proliferative
activity (M/V index, MAI and S-phase fraction). This observation
is in agreement with previous studies (Breslow, 1970; Gattuso et
al, 1990; Garbe et al, 1995; Straume and Akslen, 1996). In the
multivariate analysis, tumour thickness was the best predictor of
RFS followed by M/V index and bleeding. The best predictors of
overall survival in order of importance were MAI, bleeding, SPF
and male gender.
We found a significant association between high mitotic rate and
high SPF, and we suggest that SPF measured by FCM from paraffin
blocks can be used to predict the aggressiveness of cutaneous
malignant melanoma. However, intratumour heterogeneity of DNA
ploidy and SPF may interfere with the results when only one tumour
sample is analysed (Lipponen et al, 1991; Bergers et al, 1996).
Recently, Kirkwood et al (1996) reported promising results in
treating high-risk resected melanoma patients with adjuvant inter-
feron alfa-2b (IFNx-2b). As adjuvant treatments can be toxic and
the overall benefits with node-negative patients can be relatively
modest, a question arises: are there any subsets of high-risk node-
negative patients who would benefit from such treatments? In our
study, the combinations of MAI with bleeding, MAI with SPF and
M/V index with tumour thickness are variables that add significant
information to the normal clinical data set available.
To conclude, MAI and MN index are strong predictors of the
overall and recurrence-free survival of stage I cutaneous malignant
melanoma patients in our material. One advantage of the mitotic
indices compared with SPF is that no special equipment is needed.
200
Table 6 Independent predictors of overall survival and recurrence-free survival in Cox's analysis
Category Beta (s.e.) P-value Hazard rate (95% CI)
Overall survival
Gender
Male
Female -0.63 (0.30) 0.034 0.53 (0.30-0.95)
Bleeding 0.004 (overall)
No
Yes 1.36 (0.42) 0.001 3.89 (1.71-8.84)
NA 0.76 (0.43) 0.080 2.13 (0.91-4.98)
MAI
< 1
> 1 1.50 (0.40) 0.0002 4.47 (2.05-9.72)
SPF
<4%
> 4% 0.82 (0.32) 0.009 2.27 (1.22-4.22)
Recurrence-free survival
Bleeding 0.0106 (overall)
No
Yes 0.92 (0.31) 0.0029 2.51 (1.37-4.60)
NA 0.49 (0.32) 0.13 1.63 (0.86-3.07)
Tumour thickness (mm) 0.0021 (overall)
< 0.75
0.76-1.50 2.07 (0.75) 0.0057 7.97 (1.83-34.69)
1.51-4.0 2.33 (0.73) 0.001 10.27 (2.44-43.20)
> 4.0 2.81 (0.76) 0.0002 16.64 (3.75-73.88)
MN index
<7
>7 0.83 (0.30) 0.0058 2.31 (1.27-4.18)
Multivariate analysis included 259 patients with a complete set of data available. MAI, mitotic activity index; MN index, volume-
corrected mitotic index; SPF, S-phase fraction; NA, data not available.
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However, ifavailable, SPF is also a strong independent prognosti-
cator in stage I cutaneous malignant melanoma. We suggest that
tumour proliferation assessed by mitotic rate or SPF, together with
conventionally available prognosticators, might be considered as a
patient inclusion criteria for further adjuvant treatment trials in
node-negative cutaneous malignant melanoma patients.
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